Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2560MR)

This product GTTS-WQ2560MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Ewing sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2560MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4587MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ6603MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ1867MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ15660MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ11278MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ14664MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ5701MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ3980MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW